Kalaris Therapeutics Inc(KLRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.01 | Insider Own | 63.69% | Shs Outstand | 23.8M | Perf Week | -10.14% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 17.43% | Insider Trans | 1.79% | Shs Float | 8.6M | Perf Month | -34.62% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -0.52 | Inst Own | 19.77% | Short Float | 3.55% | Perf Quarter | -45.29% |
| Income | -0.04B | P/S | - | EPS this Y | 29.78% | Inst Trans | -2.22% | Short Ratio | 4.28 | Perf Half Y | -66.99% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | 5.48% | ROA | -46.02% | Short Interest | 0.31M | Perf YTD | -77.96% |
| Book/sh | 2.42 | P/C | 0.43 | EPS past 3/5Y | 61.69% 45.59% | ROE | -79.91% | 52W High | -84.34% ($11.88) | Perf Year | -61.73% |
| Cash/sh | 4.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -75.37% | 52W Low | 4.49% ($1.78) | Perf 3Y | -93.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.44% | Gross Margin | - | Volatility(W/M) | 7% 8.21% | Perf 5Y | -99.67% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.92 | EPS Q/Q | 20.27% | Profit Margin | - | RSI (14) | 25.1 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.92 | Sales Q/Q | - | SMA20 | -18.56% ($2.28) | Beta | 0.44 | Target Price | $18.71 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/11 | SMA50 | -39.42% ($3.07) | Rel Volume | 0.71 | Prev Close | $1.8 |
| Employees | 20 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 3.03% - | SMA200 | -66.25% ($5.51) | Avg Volume(3M) | 0.07M | Price | $1.86 |
| IPO | 2020/7/30 | Option/Short | No/Yes | Trades | 292 | Volume | 51,130 | Change | 3.33% |
KalaRys Therapeutics (KLRS) is a clinical-stage biotech company developing treatments for retinal diseases. Its lead candidate, TH103, is an anti-VEGF fusion protein designed to enhance intraocular durability, and it is being clinically developed primarily for the treatment of neovascular age-related macular degeneration (nAMD). The company is headquartered in the United States.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
KLRS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +29.8% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #431 of 594 in the industry
Based on market cap of $41M.
GRDX#428 GridAI Technologies Corp $42M PER - 
TVGN#429 Tevogen Inc $41M PER - 
ATHE#430 Alterity Therapeutics Ltd ADR $41M PER - KLRS#431 Kalaris Therapeutics Inc $41M PER - 
ESLA#432 Estrella Immunopharma Inc $41M PER - 
FAQ
What kind of company is KLRS?
KLRS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KLRS?
The market cap of KLRS is approximately $41M, ranking 4,944 within its sector.
What is the 52-week high and low for KLRS?
KLRS has recorded a 52-week high of $11.88 and a low of $1.78.
